Abstract
1 Doxazosin is a quinazoline derivative, related to prazosin, recently developed for the treatment of hypertension. 2 The intravenous administration of doxazosin (12 micrograms/kg) to six healthy normotensive subjects resulted in significant fall in erect blood pressure, with a corresponding increase in heart rate, but there were no significant changes in supine blood pressure or heart rate. 3 The changes in blood pressure and heart rate were maximal at 6 h after intravenous dosing. With prazosin the maximum effects occurred within the first hours. 4 Pressor response studies with phenylephrine confirmed that doxazosin is a relatively selective postsynaptic alpha-adrenoceptor antagonist. 5 The mean elimination half-life of doxazosin was 11 h. This compared with a T1/2 of 2.5 h for prazosin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cambridge D., Davey M. J., Massingham R. Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors [proceedings]. Br J Pharmacol. 1977 Mar;59(3):514P–515P. [PMC free article] [PubMed] [Google Scholar]
- Elliott H. L., McLean K., Sumner D. J., Meredith P. A., Reid J. L. Immediate cardiovascular responses to oral prazosin--effects of concurrent beta-blockers. Clin Pharmacol Ther. 1981 Mar;29(3):303–309. doi: 10.1038/clpt.1981.40. [DOI] [PubMed] [Google Scholar]
- Graham R. M., Thornell I. R., Gain J. M., Bagnoli C., Oates H. F., Stokes G. S. Prazosin: the first-dose phenomenon. Br Med J. 1976 Nov 27;2(6047):1293–1294. doi: 10.1136/bmj.2.6047.1293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rubin P. C., Brunton J., Meredith P. Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection. J Chromatogr. 1980 Nov 14;221(1):193–195. doi: 10.1016/s0378-4347(00)81025-7. [DOI] [PubMed] [Google Scholar]
- Timmermans P. B., Kwa H. Y., Ali F. K., van Zwieten P. A. Prazosin and its analogues UK-18,596 and UK-33,274: a comparative study on cardiovascular effects and alpha-adrenoceptor blocking activities. Arch Int Pharmacodyn Ther. 1980 Jun;245(2):218–235. [PubMed] [Google Scholar]